Arch Therapeutics Inc (ARTH) Rating Lowered to Sell at ValuEngine

Arch Therapeutics Inc (NASDAQ:ARTH) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Thursday.

Several other equities analysts have also recently issued reports on the company. Ifs Securities reaffirmed an “outperform” rating on shares of Arch Therapeutics in a research report on Tuesday, July 25th. HC Wainwright reissued a “buy” rating and set a $3.00 price target on shares of Arch Therapeutics in a report on Monday, September 18th. Finally, Zacks Investment Research cut Arch Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $2.83.

Shares of Arch Therapeutics (NASDAQ ARTH) traded down 2.19053% during mid-day trading on Thursday, hitting $0.76175. The company had a trading volume of 309,352 shares. The firm has a 50-day moving average price of $0.80 and a 200-day moving average price of $0.63. Arch Therapeutics has a 52 week low of $0.41 and a 52 week high of $0.89. The firm’s market capitalization is $111.99 million.

COPYRIGHT VIOLATION NOTICE: “Arch Therapeutics Inc (ARTH) Rating Lowered to Sell at ValuEngine” was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/2956183/arch-therapeutics-inc-arth-rating-lowered-to-sell-at-valuengine.html.

Arch Therapeutics Company Profile

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Receive News & Ratings for Arch Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.